Future kidney cancer treatments could inhibit autophagy; South Korea boosts stem cell research investment;

Cancer

> Researchers at Columbia University Medical Center have determined that inhibiting two related enzymes in mouse trials boosts survival for a lethal form of childhood leukemia. Release

> Scientists at the University of Cincinnati believe that future kidney cancer treatments could focus on inhibiting pathways involving autophagy, a mechanism in the body that gives cells nutrients from intracellular sources and can protect tumor cells from chemotherapy. Release

Stem Cells

> Scientists are the Orlando Health Heart Institute in Florida are hoping a new clinical trial will show that pelvic bone stem cells can help preserve heart muscle function after a heart attack. Release

> The South Korean government plans to substantially boost its investment this year into stem cell research and regenerative medicine, The Korea Times reports. Story

Genetics

> Changes in the gene expression of a key enzyme may be a factor in high blood pressure and susceptibility to blood clots in women with preeclampsia, researchers at Virginia Commonwealth University School of Medicine have found. Release

> The GPS2 gene appears to play a key role in regulating inflammatory response and homeostasis, Boston University School of Medicine scientists have determined. Release

And Finally... Two genes appear to affect brain size and may possibly also contribute to I.Q. and the risk of developing Alzheimer's or autism, researchers with the ENIGMA consortium have found. Story

Suggested Articles

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Selectively targeting TGF-beta1 with Scholar Rock's SRK-181 overcame primary resistance to checkpoint inhibitor therapy in mice.

Enhertu produced a 55.6% objective response rate in HER2-positive non-small cell lung cancer patients in a phase 1 trial.